Clinical utility of chromogranin A and octerotide in large cell neuro endocrine carcinoma of the uterine corpus
Shohreh Shahabi,
Ilenia Pellicciotta,
June Hou,
Sarah Graceffa,
Gloria S. Huang,
Robert N. Samuelson,
Gary L. Goldberg
Affiliations
Shohreh Shahabi
Department of Obstetrics, Gynecology, and Reproductive Biology, Danbury Hospital, Danbury, CT; Division of Gynecologic Oncology, Department of Obstetrics & Gynecology and Women's Health, Montefiore Medical Center, the Albert Einstein College of Medicine and the Albert Einstein Cancer Center, Bronx, New York
Ilenia Pellicciotta
Department of Obstetrics, Gynecology, and Reproductive Biology, Danbury Hospital, Danbury, CT; Department of Radiation Oncology, New York University School of Medicine, New York
June Hou
Division of Gynecologic Oncology, Department of Obstetrics & Gynecology and Women's Health, Montefiore Medical Center, the Albert Einstein College of Medicine and the Albert Einstein Cancer Center, Bronx, New York
Sarah Graceffa
Department of Obstetrics, Gynecology, and Reproductive Biology, Danbury Hospital, 24 Hospital Avenue, Danbury, CT
Gloria S. Huang
Division of Gynecologic Oncology, Department of Obstetrics & Gynecology and Women's Health, Montefiore Medical Center, the Albert Einstein College of Medicine and the Albert Einstein Cancer Center, Bronx, New York
Robert N. Samuelson
Department of Obstetrics, Gynecology, and Reproductive Biology, Danbury Hospital, Danbury, CT
Gary L. Goldberg
Division of Gynecologic Oncology, Department of Obstetrics & Gynecology and Women's Health, Montefiore Medical Center, the Albert Einstein College of Medicine and the Albert Einstein Cancer Center, Bronx, New York
Primary neuroendocrine tumors of the female genital tract have been described in the cervix, ovaries and uterus. Large cell neuroendocrine carcinoma (LCNC) of the uterine corpus is the least common and appears to behave the most aggressively. We report a rare case of a large cell neuroendocrine tumor of the endometrium. These tumors are not well characterized, unlike neuroendocrine tumors of the uterine cervix, consequently, the optimal management remains still unclear. The treatment of our case consisted of surgery, radiotherapy, chemotherapy, and octreotide. Despite the aggressive treatment, the patient died of disease progression 12 months after the initial diagnosis. We discuss the diagnosis, prognosis, and treatment options for LCNC of the genital tract, and potential future therapeutics.
